Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial

The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2024-10-08
DOI
https://doi.org/10.1093/cid/ciae501
Citations
3
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
1.17

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial

Julien De Greef, Sammy Huygens, Tom Lodewyck, Ine Moors et al.
3 citations
Clinical Infectious Diseases
Antifungal resistance and susceptibility
1.17
article

Superiority Trials in Invasive Aspergillosis: A Harsh Reality Check With the IA-DUET (HOVON502) Trial

Julien De Greef, Sammy Huygens, Tom Lodewyck, Ine Moors, Astrid Demandt, Elena van Leeuwen-Segarceanu, Maarten F. Corsten, Maya Hites, Laurens Nieuwenhuizen, Bart J. A. Rijnders, Robina Aerts, Katrien Lagrou, Sophie Servais, Alexander Schauwvlieghe, Johan A. Maertens, Hanne Lamberink
article en
3 citations

Abstract

The IA-DUET study aimed to compare azole-echinocandin combination therapy with azole monotherapy for invasive aspergillosis. Recruitment was hindered by patient ineligibility, competing studies, and guidelines favoring combination therapy when azole resistance was unknown. The low IA-attributable mortality suggests future trials may benefit from cluster randomization or composite endpoints to enhance efficiency.

Clinical Infectious DiseasesVol. 80(2)
Cliniques Universitaires Saint-Luc (BE), Radboud University Nijmegen (NL), University of Liège (BE), Maastricht University Medical Centre (NL), Ghent University Hospital (BE), Erasmus MC (NL), University Medical Center (US), Maastricht University (NL), St. Antonius Ziekenhuis (NL), AZ Sint-Jan (BE), Máxima Medisch Centrum (NL), Meander Medisch Centrum (NL), Maastro Clinic (NL), KU Leuven (BE)
ZonMw
Good health and well-being
Openalex Percentile: Top 21%
Antifungal resistance and susceptibility
1.17
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.